Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis

Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have foc...

Full description

Saved in:
Bibliographic Details
Published in:Breast care (Basel, Switzerland) Switzerland), 2022-12, Vol.17 (6), p.524-532
Main Authors: Batista, Marta Filipa Freire Vaz, Eiriz, Inês, Fitzpatrick, Amanda, Le Du, Fanny, Braga, Sofia, Alpuim Costa, Diogo
Format: Article
Language:English
Subjects:
Review
Review Article
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC). Summary: This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC. Key Messages: The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.
ISSN:1661-3791
1661-3805
DOI:10.1159/000526431